Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
83.63
+4.56 (5.76%)
At close: Feb 10, 2026, 4:00 PM EST
82.12
-1.50 (-1.80%)
After-hours: Feb 10, 2026, 6:48 PM EST
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $697.00K in the twelve months ending September 30, 2025, down -90.18% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
$697.00K
Revenue Growth
-90.18%
P/S Ratio
69.65
Revenue / Employee
$77,444
Employees
9
Market Cap
89.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
| Dec 31, 2023 | 10.09M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 58.42M |
| Equillium | 4.39M |
| Pyxis Oncology | 2.82M |
| ImageneBio | 800.00K |
| Precision BioSciences | 698.00K |
| iBio, Inc. | 500.00K |
| MediciNova | 257.92K |
| aTyr Pharma | 190.00K |
SPRB News
- 5 days ago - Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 7 days ago - Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - Business Wire
- 13 days ago - Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Business Wire
- 23 days ago - Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - PRNewsWire
- 4 weeks ago - Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - Business Wire
- 2 months ago - Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors - Business Wire
- 3 months ago - Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 4 months ago - Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha